These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 11020490)
1. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Saetrum Opgaard O; Nothacker H; Ehlert FJ; Krause DN Eur J Pharmacol; 2000 Oct; 406(2):265-71. PubMed ID: 11020490 [TBL] [Abstract][Full Text] [Related]
2. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Rossowski WJ; Cheng BL; Taylor JE; Datta R; Coy DH Eur J Pharmacol; 2002 Mar; 438(3):159-70. PubMed ID: 11909607 [TBL] [Abstract][Full Text] [Related]
3. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Camarda V; Rizzi A; Calò G; Gendron G; Perron SI; Kostenis E; Zamboni P; Mascoli F; Regoli D Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):141-9. PubMed ID: 11819032 [TBL] [Abstract][Full Text] [Related]
4. Augmented phosphoinositide metabolism in aortas from genetically hypertensive rats. Turla MB; Webb RC Am J Physiol; 1990 Jan; 258(1 Pt 2):H173-8. PubMed ID: 2154130 [TBL] [Abstract][Full Text] [Related]
5. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Behm DJ; Harrison SM; Ao Z; Maniscalco K; Pickering SJ; Grau EV; Woods TN; Coatney RW; Doe CP; Willette RN; Johns DG; Douglas SA Br J Pharmacol; 2003 May; 139(2):464-72. PubMed ID: 12770952 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Behm DJ; Herold CL; Ohlstein EH; Knight SD; Dhanak D; Douglas SA Br J Pharmacol; 2002 Oct; 137(4):449-58. PubMed ID: 12359626 [TBL] [Abstract][Full Text] [Related]
7. Phasic and tonic components in 5-HT2 receptor-mediated rat aorta contraction: participation of Ca++ channels and phospholipase C. Nakaki T; Roth BL; Chuang DM; Costa E J Pharmacol Exp Ther; 1985 Aug; 234(2):442-6. PubMed ID: 2410594 [TBL] [Abstract][Full Text] [Related]
8. Vascular contractile effect of urotensin II in young and aged rats: influence of aging and contribution of endothelial nitric oxide. Ishihata A; Sakai M; Katano Y Peptides; 2006 Jan; 27(1):80-6. PubMed ID: 16159683 [TBL] [Abstract][Full Text] [Related]
9. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Bottrill FE; Douglas SA; Hiley CR; White R Br J Pharmacol; 2000 Aug; 130(8):1865-70. PubMed ID: 10952676 [TBL] [Abstract][Full Text] [Related]
10. The in vivo effects of human urotensin II in the rabbit and rat pulmonary circulation: effects of experimental pulmonary hypertension. Deuchar GA; Morecroft I; Dempsie Y; Herold N; Nilsen M; Hicks MN; MacLean MR Eur J Pharmacol; 2006 May; 537(1-3):135-42. PubMed ID: 16631735 [TBL] [Abstract][Full Text] [Related]
11. Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. Behm DJ; Herold CL; Camarda V; Aiyar NV; Douglas SA Eur J Pharmacol; 2004 May; 492(2-3):113-6. PubMed ID: 15178353 [TBL] [Abstract][Full Text] [Related]
12. Role of intracellular and extracellular calcium in alpha 1-adrenoceptor-mediated vasoconstriction in the rat perfused hindquarters. Tabrizchi R Arch Int Pharmacodyn Ther; 1994; 328(1):26-38. PubMed ID: 7893189 [TBL] [Abstract][Full Text] [Related]
13. Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. Song W; McDonald J; Camarda V; Calo G; Guerrini R; Marzola E; Thompson JP; Rowbotham DJ; Lambert DG Naunyn Schmiedebergs Arch Pharmacol; 2006 May; 373(2):148-57. PubMed ID: 16596397 [TBL] [Abstract][Full Text] [Related]